Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 8, August, p. 1119–1124

doi: 10.17219/acem/94068

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Gastrointestinal non-Hodgkin lymphomas

Magdalena Olszewska-Szopa1,A,B,C,D,E,F, Tomasz Wróbel1,A,B,C,D,E,F

1 Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland

Abstract

Although gastrointestinal (GI) tract is the most common extranodal site involved in non-Hodgkin lymphoma (NHL), primary gastrointestinal NHL (gNHL) is a rare problem which concerns about 10–15% of NHL patients and 30–40% of extranodal NHL patients. Lymphoid neoplasms may consist of mature B, T and (less commonly) extranodal NK/T cells. The most common diagnoses are diffuse large B-cell lymphoma and marginal zone lymphoma (MALT), but many other lymphomas may be found in the GI tract. There are a few well-known risk factors of gNHL and some of them affect treatment. The most frequent sites of occurrence are the stomach followed by small intestine and ileocecal region. In the last 2 decades, there has been a rapid development in the diagnosis, staging and management of GI lymphoma, but still some of such lymphomas, especially T-cell ones, are a therapeutic challenge. In this review, we present clinical and pathological features of GI lymphomas. We also describe the current status in diagnosis and treatment.

Key words

DLBCL, gastrointestinal lymphoma, EATL, MALT

References (34)

  1. Bautista-Quach MA, Ake CD, Chen M, Wang J. Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features. J Gastrointest Oncol. 2012;3(3):209–225.
  2. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115(18):3664–3670.
  3. Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17(6):697–707.
  4. Foukas PG, de Leval L. Recent advances in intestinal lymphomas. Histo­pathology. 2015;66(1):112–136.
  5. Janssen J. The impact of EUS in primary gastric lymphoma. Best Pract Res Clin Gastroenterol. 2009;23(5):671–678.
  6. Byun JH, Ha HK, Kim AY, et al. CT findings in peripheral T-cell lymphoma involving the gastrointestinal tract. Radiology. 2003;227(1):59–67.
  7. Boot H. Diagnosis and staging in gastrointestinal lymphoma. Best Pract Res Clin Gastroenterol. 2010;24(1):3–12.
  8. Andrews CN, John Gill M, Urbanski SJ, Stewart D, Perini R, Beck P. Changing epidemiology and risk factors for gastrointestinal non-Hodgkin’s lymphoma in a North American population: Population-based study. Am J Gastroenterol. 2008;103(7):1762–1769.
  9. Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C. Raderer M, Ladetto M; on behalf of the ESMO Guidelines Working Group. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):144–148.
  10. Martinelli G, Gigli F, Calabrese L, et al. Early stage gastric diffuse large B-cell lymphomas: Results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. Leuk Lymphoma. 2009;50(6):925–931.
  11. Choi SY, Kim SJ, Kim WS, Kim K, Ko YH. Aggressive B cell lymphomas of the gastrointestinal tract: Clinicopathologic and genetic analysis. Virchows Arch. 2011;459(5):495–502.
  12. López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large B-cell lymphoma: Clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005;23(12):2797–2804.
  13. Nakajima Y, Tomita N, Itabashi M, et al. Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy. Leuk Res. 2015;39(2):198–203.
  14. Cuccurullo R, Govi S, Ferreri AJM. De-escalating therapy in gastric aggressive lymphoma. World J Gastroenterol. 2014;20(27):8993–8997.
  15. Avilés A, Nambo M.J, Neri N, et al. The role of surgery in primary gastric lymphoma: Results of a controlled clinical trial. Ann Surg. 2004;240(1):44–50.
  16. Kuo SH, Yeh KH, Wu MS, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H. pylori-positive gastric diffuse large B-cell lymphomas. Blood. 2012;119(21):4838–4844.
  17. Romaguera JE, Medeiros LJ, Hagemeister FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003;97(3):586–591.
  18. Dreyling M, Geisler C, Hermine O, et al; ESMO Guidelines Working Group. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii83–92. doi:10.1093/annonc/mdu264
  19. Saito M, Miyazaki M, Tanino M. ¹⁸F-FDG PET/CT imaging for a gastrointestinal mantle cell lymphoma with multiple lymphomatous polyposis. World J Gastroenterol. 2014;20(17):5141–5146.
  20. Dasappa L, Suresh Babu MC, et al. Primary gastrointestinal mantle cell lymphoma: A retrospective study. J Gastrointest Cancer. 2014;45(4):481–486.
  21. Zucca E, Bertoni F, Vannata B, Cavalli F. Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. Clin Cancer Res. 2014;20(20):5207–5216.
  22. Misdraji J, Harris NL, Hasserjian RP, Lauwers GY, Ferry JA. Primary follicular lymphoma of the gastrointestinal tract. Am J Surg Pathol. 2011;35(9):1255–1263.
  23. Damaj G, Verkarre V, Delmer A, et al. Primary follicular lymphoma of the gastrointestinal tract: A study of 25 cases and a literature review. Ann Oncol. 2003;14(4):623–629.
  24. Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program. 2008:341–348.
  25. Hoelzer D, Walewski J, Döhner H, et al; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: Report of a large prospective multicenter trial. Blood. 2014;124(26):3870–3879.
  26. Baumgaertner I, Copie-Bergman C, Levy M, et al. Complete remission of gastric Burkitt’s lymphoma after eradication of Helicobacter pylori. World J Gastroenterol. 2009;15(45):5746–5750.
  27. Zettl A, deLeeuw R, Haralambieva E, Mueller-Hermelink HK. Enteropathy-type T-cell lymphoma. Am J Clin Pathol. 2007;127(5):701–706.
  28. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115(18):3664–3670.
  29. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: Clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118(1):148–155.
  30. Nijeboer P, de Baaij LR, Visser O, et al. Treatment response in enteropathy associated T-cell lymphoma: Survival in a large multicenter cohort. Am J Hematol. 2015;90(6):493–498.
  31. Di Sabatino A, Biagi F, Gobbi PG, Corazza GR. How I treat enteropathy-associated T-cell lymphoma. Blood. 2012;119(11):2458–2468.
  32. Jantunen E, Boumendil A, Finel H, et al; Lymphoma Working Party of the EBMT. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: A retrospective study by the EBMT. Blood. 2013;121(13):2529–2532.
  33. Khalaf WF, Caldwell ME, Reddy N. Brentuximab in the treatment of CD30-positive enteropathy-associated T-cell lymphoma. J Natl Compr Canc Netw. 2013;11(2):137–140.
  34. Sibon D, Malamut G. Enteropathy-associated T-cell lymphoma type I, but not refractory celiac disease, strongly expresses CD30 and might benefit from brentuximab. Vedotin Blood. 2013;122:4252.
© Wroclaw Medical University